Galena Biopharma Doses First Patient In Phase 2 Clinical Trial With NeuVax In Combination With Herceptin To Treat High-Risk HER2 3+ Or HER2 Gene-Amplified Breast Cancer Patients
November 11, 2014 at 07:05 AM EST
Galena Biopharma, Inc. (Nasdaq: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology ...
